TY - JOUR
T1 - Effect of Repeated Administration of KT3-671, a Nonpeptide AT1 Receptor Antagonist, on Diurnal Variation in Blood Pressure, Heart Rate, and Locomotor Activity in Stroke-Prone Spontaneously Hypertensive Rats as Determined by Radiotelemetry
AU - Kawashima, Koichiro
AU - Amano, Hideto
AU - Fujimoto, Kazuko
AU - Suzuki, Takeshi
AU - Fujii, Takeshi
AU - Mochizuki, Seiichiro
AU - Tomiyama, Akira
PY - 1996
Y1 - 1996
N2 - KT3-671, a nonpeptide AT1 receptor antagonist, was administered to 20-week-old stroke-prone spontaneously hypertensive rats (SHRSP) daily for 3 weeks. Its effects on systolic, mean, and diastolic arterial blood pressure (SAP, MAP, DAP), heart rate and locomotor activity were investigated with radiotelemetry. A clear diurnal variation in blood pressure, heart rate, and loco-motor activity was observed in synchrony with the light cycle. KT3-671 at a daily dose of 10 mg/kg orally (p.o), produced a significant and consistent reduction in blood pressure, preventing the development of hypertension. KT3-671 reduced SAP more than DAP, suggesting that it may affect both vascular tone and cardiac output. Al-though KT3-671 did not affect diurnal rhythms in heart rate and locomotor activity, it did cause a slight but significant reduction in heart rate. The MAP determined 23 h after the administration of KT3-671 showed a significant reduction from the day 2 of therapy to the day 3 after discontinuation of therapy, suggesting a long duration of antihypertensive action. There was no rebound increase in blood pressure after discontinuation of KT3-671 therapy. These results suggest that KT3-671 may be potentially useful in the therapy of hypertension.
AB - KT3-671, a nonpeptide AT1 receptor antagonist, was administered to 20-week-old stroke-prone spontaneously hypertensive rats (SHRSP) daily for 3 weeks. Its effects on systolic, mean, and diastolic arterial blood pressure (SAP, MAP, DAP), heart rate and locomotor activity were investigated with radiotelemetry. A clear diurnal variation in blood pressure, heart rate, and loco-motor activity was observed in synchrony with the light cycle. KT3-671 at a daily dose of 10 mg/kg orally (p.o), produced a significant and consistent reduction in blood pressure, preventing the development of hypertension. KT3-671 reduced SAP more than DAP, suggesting that it may affect both vascular tone and cardiac output. Al-though KT3-671 did not affect diurnal rhythms in heart rate and locomotor activity, it did cause a slight but significant reduction in heart rate. The MAP determined 23 h after the administration of KT3-671 showed a significant reduction from the day 2 of therapy to the day 3 after discontinuation of therapy, suggesting a long duration of antihypertensive action. There was no rebound increase in blood pressure after discontinuation of KT3-671 therapy. These results suggest that KT3-671 may be potentially useful in the therapy of hypertension.
KW - At, receptor antagonist
KW - Diurnal blood pressure rhythm
KW - Heart rate
KW - KT3-671
KW - Radiotelemetry
KW - Stroke-prone spontaneously hypertensive rats
UR - http://www.scopus.com/inward/record.url?scp=0029918615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029918615&partnerID=8YFLogxK
U2 - 10.1097/00005344-199603000-00014
DO - 10.1097/00005344-199603000-00014
M3 - Article
C2 - 8907803
AN - SCOPUS:0029918615
SN - 0160-2446
VL - 27
SP - 411
EP - 416
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
IS - 3
ER -